Another Alzheimer's drug is in the pipeline - and it looks even better than donanemab

Another Alzheimer's drug from US pharma giant Eli Lilly is expected to perform even better than donanemab, which was this week hailed as a 'breakthrough'.

Related Keywords

United Kingdom ,Sweden ,Oregon ,United States ,Britain ,Britons ,Eli Lilly ,Alois Alzheimer ,Ivan Koychev ,Giles Hardingham ,Glori Weiss ,National Institute For Health ,Oxford University Dementia Platform United Kingdom ,United Kingdom Dementia Research Institute ,Alzheimer Association ,National Institute ,Care Excellence ,Oxford University ,Dementia Platform United Kingdom ,Dailymail ,Health ,Alzheimers Disease ,